3-(4-(6-(3-(2-methoxyacetamido)prop-1-ynyl)quinazolin-4-ylamino)-2-methylphenoxy)-N,N-dimethylbenzamide

ID: ALA230785

Chembl Id: CHEMBL230785

PubChem CID: 44426265

Max Phase: Preclinical

Molecular Formula: C30H29N5O4

Molecular Weight: 523.59

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COCC(=O)NCC#Cc1ccc2ncnc(Nc3ccc(Oc4cccc(C(=O)N(C)C)c4)c(C)c3)c2c1

Standard InChI:  InChI=1S/C30H29N5O4/c1-20-15-23(11-13-27(20)39-24-9-5-8-22(17-24)30(37)35(2)3)34-29-25-16-21(10-12-26(25)32-19-33-29)7-6-14-31-28(36)18-38-4/h5,8-13,15-17,19H,14,18H2,1-4H3,(H,31,36)(H,32,33,34)

Standard InChI Key:  DPGKUIBMCVPINF-UHFFFAOYSA-N

Associated Targets(Human)

ERBB2 Tclin Receptor protein-tyrosine kinase erbB-2 (7851 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ERBB2 Tclin Epidermal growth factor receptor and ErbB2 (HER1 and HER2) (186 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 523.59Molecular Weight (Monoisotopic): 523.2220AlogP: 4.29#Rotatable Bonds: 8
Polar Surface Area: 105.68Molecular Species: NEUTRALHBA: 7HBD: 2
#RO5 Violations: 1HBA (Lipinski): 9HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 12.11CX Basic pKa: 4.07CX LogP: 4.02CX LogD: 4.02
Aromatic Rings: 4Heavy Atoms: 39QED Weighted: 0.33Np Likeness Score: -1.62

References

1. Lippa B, Kauffman GS, Arcari J, Kwan T, Chen J, Hungerford W, Bhattacharya S, Zhao X, Williams C, Xiao J, Pustilnik L, Su C, Moyer JD, Ma L, Campbell M, Steyn S..  (2007)  The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.,  17  (11): [PMID:17398092] [10.1016/j.bmcl.2007.03.046]

Source